Related Experiment Video

Updated: Jun 7, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective

Jun Hirai1,2,3, Nobuaki Mori1,2, Yuki Hanai4

  • 1Department of Clinical Infectious Diseases, Aichi Medical University Hospital, Aichi 480-1195, Japan.

Antibiotics (Basel, Switzerland)
|March 28, 2025
PubMed

Insights

Fidaxomicin plus bezlotoxumab significantly improved cure rates for high-risk recurrent Clostridioides difficile infection (CDI) patients compared to fidaxomicin alone, offering a promising CDI management strategy.

Area of Science:

  • Infectious Diseases
  • Gastroenterology
  • Pharmacology

Background:

  • Clostridioides difficile infection (CDI) recurrence affects 30% of patients, increasing morbidity and healthcare costs.
  • Fidaxomicin (FDX) and bezlotoxumab (BEZ) show promise in preventing CDI recurrence.
  • Limited real-world data exist on the combination of FDX + BEZ in high-risk CDI patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of FDX + BEZ versus FDX alone in CDI patients with recurrence risk factors.
  • To assess the impact of combination therapy on cure rates and recurrence.
  • To identify factors associated with improved clinical outcomes in high-risk CDI.

Main Methods:

  • Retrospective analysis of 82 high-risk CDI patients treated with FDX alone or FDX + BEZ.
  • Inclusion criteria: ≥2 recurrence risk factors, FDX treatment ≥10 days.
  • Outcomes: Recurrence, global/clinical cure rates, adverse events, and diarrhea resolution time.

Main Results:

  • FDX + BEZ group (n=30) showed significantly higher global (86.7% vs 65.4%) and clinical cure rates (90.0% vs 69.2%) (p<0.05).
  • Recurrence rates were non-significantly lower in the FDX + BEZ group (3.3% vs 11.5%).
  • Multivariate analysis indicated FDX + BEZ significantly improved clinical cure (aOR 4.167).

Conclusions:

  • FDX + BEZ therapy demonstrates superior efficacy and safety in high-risk CDI patients.
  • Combination therapy accelerates diarrhea resolution without increasing adverse events.
  • FDX + BEZ represents a promising strategy for optimizing CDI management.

Keywords:
Clostridioides difficilebezlotoxumabcombination therapyfidaxomicinrecurrencesevere diarrhea

More Related Videos

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R2029106:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...